Loading...
Loading...
In a report published Monday, Goldman Sachs analyst Terence Flynn reiterated a Buy rating on
Regeneron PharmaceuticalsREGN, and raised the price target from $329.00 to $355.00.
In the report, Goldman Sachs noted, “REGN reported complete Phase 3 data for key eye drug, Eylea for a new indication (DME, vision loss due to diabetes) at the Retina Society conference. The data were in line with our expectations and we anticipate they will support approval for a broader label and drive uptake/growth.”
Regeneron Pharmaceuticals closed on Friday at $305.65.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in